Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

405 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Kitagawa J, Aoi A, Nishikawa R. Narita Y, et al. Among authors: fukuhara n. Neuro Oncol. 2021 Jan 30;23(1):122-133. doi: 10.1093/neuonc/noaa145. Neuro Oncol. 2021. PMID: 32583848 Free PMC article. Clinical Trial.
Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
Maruyama D, Nagai H, Fukuhara N, Kitano T, Ishikawa T, Shibayama H, Choi I, Hatake K, Uchida T, Nishikori M, Kinoshita T, Matsuno Y, Nishikawa T, Takahara S, Tobinai K. Maruyama D, et al. Among authors: fukuhara n. Cancer Sci. 2016 Dec;107(12):1785-1790. doi: 10.1111/cas.13076. Epub 2016 Nov 25. Cancer Sci. 2016. PMID: 27616553 Free PMC article. Clinical Trial.
Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
Ogura M, Ishizawa K, Maruyama D, Uike N, Ando K, Izutsu K, Terui Y, Imaizumi Y, Tsukasaki K, Suzuki K, Izumi T, Usuki K, Kinoshita T, Taniwaki M, Uoshima N, Suzumiya J, Kurosawa M, Nagai H, Uchida T, Fukuhara N, Choi I, Ohmachi K, Yamamoto G, Tobinai K; Japanese Bendamustine Lymphoma Study Group. Ogura M, et al. Among authors: fukuhara n. Int J Hematol. 2017 Apr;105(4):470-477. doi: 10.1007/s12185-016-2146-4. Epub 2016 Nov 29. Int J Hematol. 2017. PMID: 27900638 Clinical Trial.
Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.
Maruyama D, Hatake K, Kinoshita T, Fukuhara N, Choi I, Taniwaki M, Ando K, Terui Y, Higuchi Y, Onishi Y, Abe Y, Kobayashi T, Shirasugi Y, Tobinai K. Maruyama D, et al. Among authors: fukuhara n. Cancer Sci. 2017 May;108(5):1007-1012. doi: 10.1111/cas.13230. Epub 2017 May 19. Cancer Sci. 2017. PMID: 28267244 Free PMC article. Clinical Trial.
Phase III study of watchful waiting vs. rituximab as first-line treatment in advanced stage follicular lymphoma with low tumour burden (JCOG1411, FLORA study).
Miyamoto K, Fukuhara N, Maruyama D, Shibata T, Nakamura K, Ishizawa K, Tsukasaki K, Nagai H; Lymphoma Study Group of the Japan Clinical Oncology Group. Miyamoto K, et al. Among authors: fukuhara n. Jpn J Clin Oncol. 2018 Aug 1;48(8):777-780. doi: 10.1093/jjco/hyy085. Jpn J Clin Oncol. 2018. PMID: 29901705 Clinical Trial.
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.
Munakata W, Ando K, Hatake K, Fukuhara N, Kinoshita T, Fukuhara S, Shirasugi Y, Yokoyama M, Ichikawa S, Ohmachi K, Gion N, Aoi A, Tobinai K. Munakata W, et al. Among authors: fukuhara s, fukuhara n. Cancer Sci. 2019 May;110(5):1686-1694. doi: 10.1111/cas.13983. Epub 2019 Mar 28. Cancer Sci. 2019. PMID: 30815927 Free PMC article. Clinical Trial.
Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma.
Izutsu K, Minami Y, Fukuhara N, Terui Y, Jo T, Yamamoto G, Ishikawa T, Kobayashi T, Kiguchi T, Nagai H, Ohtsu T, Kalambakas S, Fustier P, Midorikawa S, Tobinai K. Izutsu K, et al. Among authors: fukuhara n. Int J Hematol. 2020 Mar;111(3):409-416. doi: 10.1007/s12185-019-02802-y. Epub 2019 Dec 19. Int J Hematol. 2020. PMID: 31858429 Clinical Trial.
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial.
Shimada K, Yamaguchi M, Atsuta Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto M, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Izumi T, Kin Y, Tsukasaki K, Hashimoto D, Yuge M, Yanagisawa A, Kuwatsuka Y, Shimada S, Masaki Y, Niitsu N, Kiyoi H, Suzuki R, Tokunaga T, Nakamura S, Kinoshita T. Shimada K, et al. Among authors: fukuhara n. Lancet Oncol. 2020 Apr;21(4):593-602. doi: 10.1016/S1470-2045(20)30059-0. Epub 2020 Mar 11. Lancet Oncol. 2020. PMID: 32171071 Clinical Trial.
405 results